Peplomycin

Peplomycin (Bleomycin PEP) is an analog of Bleomycin (HY-108345) and an antitumor antibiotic. Peplomycin exhibits potent antitumor activity and relatively low pulmonary toxicity. Peplomycin can induce various skin abnormalities and trigger apoptosis in SSCKN cells of oral squamous cell carcinoma. Peplomycin can also induce pulmonary fibrosis. Peplomycin is applicable for the research of tumors, pulmonary fibrosis and other related diseases^[1][2][3][4]. In Vitro:Peplomycin (0-100 μM; 30 h) inhibits human oral squamous carcinoma cell line SSCKN and SCCTF cells in a dose-dependent manner^[3].
Peplomycin (1 μM and 10 μM; 30 h) results nuclear fragmentation and condensation of chromatin in cells dose-dependently and induces apoptosis^[3].
Peplomycin (5 mg/mL; 7 d) induces pulmonary fibrosis separated from saline-injected rats (N-Fib) by differentiating fibroblasts to alpha-SMA-positive MF^[4].
In Vivo:Peplomycin (5 mg/kg; once daily) induces rat pulmonary fibroblasts to myofibroblasts (MF), while the peripheries of lungs adjacent to the pleura reveals advanced fibrosis with a small number of alpha-smooth muscle actin (alpha-SMA)-positive MF, which ultrastructurally possessed abundant microfilaments and cellular organelles^[4].